Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid

Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid

The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria fo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2009-12, Vol.49 (12), p.1946-1946
Hauptverfasser: Lechowicz, Maryjo, Dittmer, Dirk P., Lee, Jeannette Y., Krown, Susan E., Wachsman, William, Aboulafia, David, Dezube, Bruce J., Ratner, Lee, Said, Jonathan, Ambinder, Richard F.
Format: Artikel
Sprache:eng
Schlagworte:
Acquired immune deficiency syndrome
Acquired Immunodeficiency Syndrome - complications
Adult
AIDS
Biological and medical sciences
Blood
Chemical compounds
Clinical trials
Dermatology
Female
Herpesviridae
Herpesvirus
Herpesvirus 8, Human - isolation & purification
HIV
HIV/AIDS
Human herpesvirus 8
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Kaposi sarcoma
Kaposis sarcoma
Male
Medical sciences
Medical treatment
Messenger RNA
Middle Aged
Prospective Studies
RNA
RNA, Viral - analysis
Sarcoma, Kaposi - drug therapy
T lymphocytes
Toxicity
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Valproic Acid - therapeutic use
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The AIDS Malignancy Consortium undertook a pilot trial of valproic acid among patients with AIDS-associated Kaposi sarcoma (KS). Treatment was associated with low toxicity, but the KS clinical response and KS herpesvirus lytic induction rates were not sufficiently high to meet predefined criteria for efficacy.
ISSN:1058-4838
1537-6591
DOI:10.1086/648447